Active substance
Eletriptan
- SFDA 9
- US FDA 10
- Health Canada 16
- US price lines 4
- NHS prices 2
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Eleptan | 40 mg | Film-coated tablet · Oral use | 6 Blister | SAR 67.85 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| Eleptan | 40 mg | Film-coated tablet · Oral use | 3 Blister | SAR 38.50 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| Eletrivaz | 40 mg | Tablet · Oral use | 6 Blister | SAR 73.50 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Migrotan | 40 mg | Film-coated tablet · Oral use | 4 Blister | SAR 59.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Migrotan | 40 mg | Film-coated tablet · Oral use | 10 Blister | SAR 131.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| RELPAX 20MG TABLET | 20 mg | Film-coated tablet · Oral use | 3 Blister | SAR 58.20 | NCE · Prescription | PFIZER SAUDI LIMITED | Valid |
| RELPAX 20MG TABLET | 20 mg | Film-coated tablet · Oral use | 6 Blister | SAR 113.85 | NCE · Prescription | PFIZER SAUDI LIMITED | Valid |
| RELPAX 40MG TABLET | 40 mg | Film-coated tablet · Oral use | 3 Blister | SAR 48.15 | NCE · Prescription | Viatris Arabia Limited | Valid |
| RELPAX 40MG TABLET | 40 mg | Film-coated tablet · Oral use | 6 Blister | SAR 84.83 | NCE · Prescription | Viatris Arabia Limited | Valid |
Indications — CHI Daman Drug Formulary
MIGRAINE/ HEADACHE; POLYCYTHEMIA VERA - MIGRAINES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RELPAX | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | UPJOHN | Prescription | 26 Dec 2002 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ZYDUS PHARMS | Prescription | 16 Jun 2017 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | TEVA PHARMS USA | Prescription | 27 Jun 2017 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | MYLAN | Prescription | 11 Aug 2017 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | CHARTWELL RX | Prescription | 29 Aug 2017 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 15 Jan 2019 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | REGCON HOLDINGS | Prescription | 13 Jul 2022 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ANNORA PHARMA | Prescription | 7 Jul 2025 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | STEVENS J | Discontinued | 25 May 2018 |
| ELETRIPTAN HYDROBROMIDE | EQ 20MG BASE; EQ 40MG BASE | tablet · oral | CARLSBAD | Discontinued | 13 Jul 2020 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-ELETRIPTAN TABLETS | 02518015 | 20 MG | TABLET · ORAL | APOTEX INC |
| APO-ELETRIPTAN TABLETS | 02518023 | 40 MG | TABLET · ORAL | APOTEX INC |
| AURO-ELETRIPTAN | 02479451 | 20 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ELETRIPTAN | 02479478 | 40 MG | TABLET · ORAL | AURO PHARMA INC |
| ELETRIPTAN | 02511266 | 20 MG | TABLET · ORAL | SANIS HEALTH INC |
| ELETRIPTAN | 02511274 | 40 MG | TABLET · ORAL | SANIS HEALTH INC |
| JAMP ELETRIPTAN | 02493683 | 20 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP ELETRIPTAN | 02493691 | 40 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| PRO-ELETRIPTAN | 02489961 | 20 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRO-ELETRIPTAN | 02489988 | 40 MG | TABLET · ORAL | PRO DOC LIMITEE |
| RELPAX | 02256290 | 20 MG | TABLET · ORAL | BGP PHARMA ULC |
| RELPAX | 02256304 | 40 MG | TABLET · ORAL | BGP PHARMA ULC |
| TEVA-ELETRIPTAN | 02382091 | 20 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-ELETRIPTAN | 02382105 | 40 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| VTRS-ELETRIPTAN | 02342235 | 20 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| VTRS-ELETRIPTAN | 02342243 | 40 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ELETRIPTAN HBR 20 MG TABLET | $1.72929 | per EA | 23 Sep 2026 |
| US NADAC | ELETRIPTAN HBR 40 MG TABLET | $1.74515 | per EA | 23 Sep 2026 |
| US NADAC | RELPAX 20 MG TABLET | $77.37047 | per EA | 23 Sep 2026 |
| US NADAC | RELPAX 40 MG TABLET | $77.04869 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Eletriptan 20mg tablets | £22.50 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Eletriptan 40mg tablets | £23.65 | 6 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.5.1. Medicines for acute migraine attacks · core
Therapeutic equivalent to sumatriptan for Migraine
Safety signals and safety-related labeling changes
- US FDA 25 Mar 2020 RELPAX — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.